吉西他滨联合奥沙利铂对进展期胆囊癌的临床疗效
发布时间：2018-10-10 17:27
【摘要】：目的探讨介入栓塞化疗对不可切除胆囊癌的临床疗效。方法选取我院2012年3月至2017年3月收治的30例不可切除胆囊癌患者作为观察对象。根据治疗方式的不同,分为对照组和实验组,其中对照组13例采用吉西他滨+奥沙利铂的全身新辅助静脉化疗方案,实验组17例全部采取经肝动脉插管局部栓塞化疗。观察两组病人的近期有效率、获益率、肿瘤直径有无变化和不良反应的差异。结果栓塞化疗组近期临床疗效优于新辅助化疗组(P=0.0050.05),有效率高于新辅助化疗组(P=0.0020.05),但介入栓塞化疗组和新辅助化疗组获益率无显著差异(P=0.0610.05)。两组治疗后肿瘤直径均明显缩小(P0.05),且介入栓塞化疗组肿瘤直径[(1.8±0.3)cm]小于新辅助化疗组[(3.5±0.7)cm](P=0.0010.05)。两组的发热率、胃肠道反应发生率无明显差异(P0.05),但介入栓塞化疗组腹痛的发生率(83.4%)高于新辅助化疗组(38.5%),骨髓抑制率(29.4%)低于新辅助化疗组(76.9%)。两组腹痛发生率、骨髓抑制发生率差异有统计学意义(P0.05)。结论栓塞化疗和新辅助化疗均对晚期胆囊癌有较好的近期疗效,但相对于全身新辅助化疗,介入栓塞化疗近期疗效更好,安全可行,值得临床推广。
[Abstract]:Objective to investigate the clinical effect of interventional chemoembolization on unresectable gallbladder carcinoma. Methods 30 patients with unresectable gallbladder carcinoma admitted in our hospital from March 2012 to March 2017 were selected as observation objects. According to the different treatment methods, the patients in the control group were divided into two groups: the control group (n = 13) was treated with gemcitabine oxaliplatin, and the control group (n = 17) was treated with transcatheter hepatic artery chemoembolization (TACE). The short-term effective rate, benefit rate, tumor diameter and adverse reactions were observed. Results the short-term clinical efficacy of embolization chemotherapy group was better than that of neo-adjuvant chemotherapy group (P0. 0050.05), and the effective rate was higher than that of neoadjuvant chemotherapy group (P0. 0020.05), but there was no significant difference between interventional chemoembolization group and neoadjuvant chemotherapy group (P0. 0610.05). The diameter of tumor decreased significantly in both groups after treatment (P0.05), and the diameter of tumor in interventional chemoembolization group [(1.8 卤0.3) cm] was lower than that in neoadjuvant chemotherapy group [(3.5 卤0.7) cm] (P0. 0010.05). There was no significant difference in the incidence of fever and gastrointestinal reaction between the two groups (P0.05), but the incidence of abdominal pain in the interventional chemoembolization group (83.4%) was higher than that in the neo-adjuvant chemotherapy group (38.5%), and the bone marrow inhibition rate (29.4%) was lower than that in the neo-adjuvant chemotherapy group (76.9%). The incidence of abdominal pain and bone marrow suppression were significantly different between the two groups (P0.05). Conclusion both chemoembolization and neoadjuvant chemotherapy are effective in the treatment of advanced gallbladder carcinoma, but compared with systemic neoadjuvant chemotherapy, interventional chemoembolization is more effective, safe and feasible, and worthy of clinical promotion.
【学位授予单位】：重庆医科大学
【学位级别】：硕士
【学位授予年份】：2017
【分类号】：R735.8
本文编号：2262654
[Abstract]:Objective to investigate the clinical effect of interventional chemoembolization on unresectable gallbladder carcinoma. Methods 30 patients with unresectable gallbladder carcinoma admitted in our hospital from March 2012 to March 2017 were selected as observation objects. According to the different treatment methods, the patients in the control group were divided into two groups: the control group (n = 13) was treated with gemcitabine oxaliplatin, and the control group (n = 17) was treated with transcatheter hepatic artery chemoembolization (TACE). The short-term effective rate, benefit rate, tumor diameter and adverse reactions were observed. Results the short-term clinical efficacy of embolization chemotherapy group was better than that of neo-adjuvant chemotherapy group (P0. 0050.05), and the effective rate was higher than that of neoadjuvant chemotherapy group (P0. 0020.05), but there was no significant difference between interventional chemoembolization group and neoadjuvant chemotherapy group (P0. 0610.05). The diameter of tumor decreased significantly in both groups after treatment (P0.05), and the diameter of tumor in interventional chemoembolization group [(1.8 卤0.3) cm] was lower than that in neoadjuvant chemotherapy group [(3.5 卤0.7) cm] (P0. 0010.05). There was no significant difference in the incidence of fever and gastrointestinal reaction between the two groups (P0.05), but the incidence of abdominal pain in the interventional chemoembolization group (83.4%) was higher than that in the neo-adjuvant chemotherapy group (38.5%), and the bone marrow inhibition rate (29.4%) was lower than that in the neo-adjuvant chemotherapy group (76.9%). The incidence of abdominal pain and bone marrow suppression were significantly different between the two groups (P0.05). Conclusion both chemoembolization and neoadjuvant chemotherapy are effective in the treatment of advanced gallbladder carcinoma, but compared with systemic neoadjuvant chemotherapy, interventional chemoembolization is more effective, safe and feasible, and worthy of clinical promotion.
【学位授予单位】：重庆医科大学
【学位级别】：硕士
【学位授予年份】：2017
【分类号】：R735.8
【参考文献】
相关期刊论文 前10条
1 王毓锋;施宝民;;新时代下的微创胆道外科技术[J];世界华人消化杂志;2016年19期
2 李新慧;冯志强;张洪义;刘洋;汪鑫;陈智;;射频消融联合胆道支架治疗恶性梗阻性黄疸31例分析[J];人民军医;2016年07期
3 卡哈尔曼·力提埔;;原发性胆囊癌的CT、MRI诊断作用分析[J];中外医疗;2016年13期
4 苗燕;刘利平;;胆囊良恶性病变的影像学诊断现状及研究进展[J];医学综述;2016年07期
5 董家鸿;王剑明;曾建平;;胆囊癌诊断和治疗指南(2015版)[J];临床肝胆病杂志;2016年03期
6 徐捚耀;姜海;王捷;;规范化胆囊癌根治术[J];消化肿瘤杂志(电子版);2015年04期
7 朱云楼;王巍;;胆囊癌T_1期手术方式的选择[J];外科理论与实践;2015年05期
8 丁婕;戴旭;孟宪运;王冠;;实体瘤疗效评价标准的研究进展[J];中国肿瘤临床与康复;2015年09期
9 王洪海;李敏;邵换璋;秦秉玉;;疏肝利胆汤对胆囊癌术后化疗患者生活质量及免疫功能的影响[J];陕西中医;2015年08期
10 彭腊么;彭所明;朱洪;;原发性胆囊癌的早期诊断进展[J];分子影像学杂志;2015年02期
，本文编号：2262654
本文链接：https://www.wllwen.com/yixuelunwen/zlx/2262654.html
